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Abstract
Knowledge translation (KT) involves implementation of evidence-based strategies and guidelines into practice to
improve the process of care and health outcomes for patients. Findings from pragmatic trials may be used in KT
to provide patients, healthcare providers and policymakers with information to optimize healthcare decisions
based on how a given strategy or intervention performs under the real world conditions. However, pragmatic
trials have been criticized for having the following problems: i) high rates of loss to follow-up; ii)
nonadherence to study intervention; iii) unblinded treatment and patient self-assessment, which can potentially create
bias; iv) being less perfect experiments than efficacy trials; v) sacrificing internal validity to achieve generalizability; and
vi) often requiring large sample sizes to detect small treatment effects in heterogeneous populations. In this paper, we
discuss whether these criticisms hold merit, or if they are simply driven by confusion about the purpose of pragmatic
trials. We use the Cardiovascular Health Awareness Program (CHAP) trial - a community randomized pragmatic trial
designed to assess whether offering a highly organized, community-based CHAP intervention compared to usual care
can reduce cardiovascular disease-related outcomes - to address these specific criticisms and illustrate how to reduce
this confusion.
Trial registration: Current controlled trials ISRCTN50550004 (9 May 2007).
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Background
The Canadian Institutes of Health Research (CIHR)
defines knowledge translation (KT) as a “dynamic and
iterative process that includes synthesis, dissemination,
exchange and ethically sound application of knowledge to
improve the health of Canadians, provide more effective
health services and products and strengthen the health
care system” [1]. Thus, KT is a quality improvement
process whose ultimate goal is to promote the use of
evidence to support practice and policy. KT researchers
have noted that whereas KT promotes evidence-based
practice (EBP), the methods used to promote EBP are
not always necessarily evidence-based [2]. As such,
randomized controlled trials of KT interventions play a
significant role in the KT process. These KT trials are
designed based on the following considerations: i) the
right PICOT (population; intervention; comparator;
outcomes; time-frame) research question that is relevant
to patients, healthcare providers and policy-makers; ii) the
right methodology, such as a randomized controlled tri-
als (RCT), to minimize bias; iii) large sample sizes - to
maintain sufficient power to account for heterogeneity of
populations studied and variability in the estimated treat-
ment effects; and most importantly iv) a pragmatic
strategy in design, conduct and analysis - to optimize
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the relevance of the results for real world practice
and decision-making.
What is a pragmatic strategy?
The Oxford English Dictionary defines “pragmatic” as an
adjective meaning “Dealing with matters in accordance
with practical rather than theoretical considerations or
general principles; aiming at what is achievable rather
than ideal; matter-of-fact, practical, down-to-earth” [3].
Inspired by Schwartz and Lellouch’s work [4], a prag-
matic approach requires that when comparing treat-
ments in the “real world,” one should take into account:
1. The realities of life - that patients may change or
withdraw treatment, may not adhere to treatment,
and may experience barriers to treatment.
2. The patient, provider and policy-maker have
preferences and pressures.
3. Practice variations among healthcare providers.
4. The existence of co-morbid conditions - patients
may take multiple medications (which can interact
with the treatment of primary interest).
5. Variations in decision-making processes between
administrators or policy-makers, including funders.
A pragmatic trial is designed to answer the practical
question of whether offering an intervention compared
with some alternative (for example, usual care) within
the real world environment does more good than harm.
That is, a pragmatic trial addresses a question of whether
an intervention does work under usual healthcare con-
ditions in patients to whom it is offered [5, 6]. Other
synonymous terms used for a pragmatic trial include prac-
tical, management or effectiveness trial. On the other hand,
explanatory trials, also known as efficacy trials are de-
signed to test whether an intervention can work under
ideal, tightly controlled conditions in patients who receive
it [5, 6]. They are therefore intentionally designed not to
be pragmatic.
A key advantage of a pragmatic trial is that, if its
result is positive (that is, the intervention is shown to
cause more good than harm), one can be reasonably
sure that the therapy being tested really works and
can be successfully implemented in real practice. A
disadvantage is that if its result is negative (that is, it
is unclear whether the intervention does more harm
than good), one cannot distinguish a worthless ther-
apy from an efficacious therapy that is not applied or
accepted widely enough by the participants. Hence, in
pragmatic trials, it is better to test therapies that have
already been shown to work in explanatory trials. On
the other hand, the main advantage of explanatory
trials is that if they are negative, one can abandon
the therapy; a disadvantage is that if they are positive,
one still does not know whether the therapy will
work in usual healthcare conditions. Thus, positive
explanatory trials still require therapies to be tested
further in pragmatic trials, in order to assess their ef-
fects in real-world settings.
For some key resources on pragmatic and explanatory
trials and the differences between them, we refer the
reader to the clinician-trialist rounds by Dr. David Sackett
[5, 7], where he reviews the main features of pragmatic
trials, and MacPherson [6]. See Table 1 for additional
resources on pragmatic trials and related issues.
In this paper, we will discuss some of the key criticisms
and confusion around pragmatic trials, whether or not
these criticisms hold merit, and use the Cardiovascular
Health Awareness Program (CHAP) trial, a community
randomization pragmatic trial designed to assess whether
offering a highly organized, community-based CHAP
intervention compared to usual care can reduce cardio-
vascular disease (CVD) related outcomes [8], to illustrate
how to address the issues.
Main text
Confusions and controversies about pragmatic trials and
how to deal with them
Pragmatic trials have been heavily criticized in the litera-
ture [9] for the following reasons: i) high rates of loss to
follow-up; ii) nonadherence to study intervention; iii)
unblinded treatment and patient self-assessment, which
can potentially create bias; iv) being less perfect experi-
ments than efficacy trials; v) sacrificing internal validity
to achieve generalizability; and vi) often requiring large
sample sizes to detect small treatment effects in hetero-
geneous populations. The first three (i-iii) suggest that
pragmatic trials may lead to biased estimates of effect of
therapies or interventions, whereas the last three (iv, v
and vi) suggest that pragmatic trials may not be a good
use of research funds or may be infeasible to conduct.
The key issue is whether these criticisms are a funda-
mental problem in real-world health care. Do real-world
patients know what treatment they are supposed to take,
but often do not take it as prescribed, drop out of care,
etcetera? If so, the problem must be permitted to occur,
in order to get a clear answer as to whether the under-
lying therapy works in the real world. The more signifi-
cant challenge in pragmatic trials is to prevent the
problem from leading to a biased conclusion.
In the next section, we describe our experiences in
designing and conducting a KT trial using a pragmatic
strategy - the CHAP trial designed to implement evidence-
based guidelines to improve cardiovascular health among
the elderly in Ontario communities - to illustrate how one
can address these criticisms in the design, conduct and
analysis of a pragmatic trial.
Thabane et al. Trials  (2015) 16:387 Page 2 of 8
Ethics
The CHAP trial was approved by the research ethics
boards at Bruyère Continuing Care in Ottawa, Sunnybrook
Health Sciences Centre in Toronto, and McMaster Univer-
sity in Hamilton. Informed consent was obtained from
each participant.
Addressing the criticisms: the CHAP trial
Cardiovascular diseases account for about 30 % of all
deaths around the world, with more than 50 % of
deaths due to stroke and about 15 % attributable to
hypertension [10]. Hypertension is one of the leading
risk factors for death in North America [10]. It is a
major risk factor for cardiovascular disease (CVD), and
a leading cause of hospitalization, disability and death
in North America [11, 12]. In Canada, the burden of
CVD is huge - with one CVD or stroke death every
7 min. Cardiovascular disease accounts for 17 % of the
total hospitalizations and over CAN $22 billion is
spent each year on CVD problems [13]. We know from
efficacy or explanatory CVD trials that a decrease of
10 mmHg in systolic blood pressure or 5 mm. Hg in
diastolic blood pressure (with one medication or
a change in lifestyle) significantly improve health
outcomes: they can reduce heart failures by 50 %,
strokes by 40 % and death or heart attacks by 10-15 %
[14, 15]. However, we also know that major gaps exist
in making efficacious therapies or interventions
effective in the real world. For example, detection,
treatment and control of hypertension remain sub-
optimal, with only half of the people with hypertension
actually being diagnosed; of those diagnosed, only half
are treated, and of those treated, only half control their
hypertension - a phenomenon that is seen in many
diseases and referred to as the rule of halves [16].
Many people are unaware they have high blood pres-
sure (BP), which is why hypertension is often called
“the silent killer” [17]. Furthermore, recommended
techniques for BP measurement are rarely followed,
and community-based interventions are often not
linked to primary care.
The CHAP study was a cluster randomization trial,
with the community as the unit of randomization,
intervention, analysis and inference, designed to
address the CVD problems created by hypertension
[8]. Its PICOT (population, intervention, control, out-
comes and time-frame) question was as indicated
below:
Table 1 Administrative database sources used for the Cardiovascular Health Awareness Program (CHAP) evaluation
Database Description of contents
The Census data Contains the sociodemographic profile and a measure of deprivation associated with different
regions (small regions called dissemination areas).
The Client Agency Enrolment Program Tracks patient enrollment to individual family physicians.
The Corporate Provider Database Captures physician demographic and training information, and tracks their enrolment in practices
and the primary care service organizations.
The Discharge Abstract Database Provides information on all acute care hospitalizations.
The National Ambulatory Care Reporting System
(NACRS)
Provides information on all emergency department encounters and same day surgeries.
The Ontario Drug Benefit Program Database Tracks all provincially reimbursed prescription drug products dispensed to Ontarians aged 65 years
and older or receiving social assistance.
The Ontario Health Insurance Plan Claims History
Database
Captures information regarding in-and-out patient physician services and outpatient diagnostic and
laboratory services.
The Ontario Physician Human Resources
Database
Identifies area of specializations for physicians and allows primary care providers who are generalists
to be identified.
The Registered Person’s Database Captures demographic information and vital status (alive/deceased) for all Ontarians insured under
the Ontario Health Insurance Plan
The Statistics Canada’s Postal Code Conversion
File
Allows patients to be attributed to a census dissemination area based on postal code.
• P: Among midsized Ontario communities,
• I: does a highly organized, community-based program that combines
offering blood pressure assessments and recording of CVD risks to
everybody > 65 years old with peer health volunteer-delivered
education and referral of all new or uncontrolled hypertensives to a
source of continuing care (CHAP session),
• C: compared with usual care (that is, absence of this community-
based program),
• O: reduce community rates of hospitalization for acute myocardial
infarction, stroke and congestive heart failure
• T: over 12 months?
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Thirty-nine communities were selected, stratified by
size and geographical location, and randomly allocated
to intervention (20 communities) and control (19
communities) arms. A detailed description of the de-
sign and development of the CHAP trial has been
published elsewhere, [18–21], along with the main
results [8].
How pragmatic was the CHAP trial?
Figure 1 shows the PRECIS (pragmatic-explanatory con-
tinuum indicator summary) diagram for the CHAP
trial based on scoring by five CHAP investigators
(Lisa Dolovich, Larry W Chambers, Lehana Thabane,
Janusz Kaczorowski and J Michael Paterson). Intro-
duced in 2009, the PRECIS is a tool that can be used
to indicate the level of pragmatism of a trial on 10
elements [22]. The wider the web on the PRECIS
wheel, the more pragmatic a trial design is, and the
closer it is to the center of the wheel, the more ex-
planatory it is. Judging from the PRECIS wheel for
the CHAP trial, the CHAP investigators believed that
CHAP was a highly pragmatic trial. Scoring was done
independently by five investigators and the scores of
each investigator are shown as a green dot in the
Fig. 1.
The CHAP intervention was followed by a statistically
significant 9 % relative reduction (RR) in our composite
endpoint of hospitalization for acute myocardial in-
farction (MI), congestive failure or stroke. There
were statistically significant reductions favoring the
intervention communities in hospital admissions for
acute MI and congestive HF, but not for stroke. Ex-
trapolating to the general population aged 65 years,
the 9 % RR means that the CHAP intervention
would result in approximately 5,000 fewer hospital
admissions for CVD annually in Ontario.
How did we address the key criticisms about pragmatic
trials in the CHAP trial?
Criticism 1: High rate of loss to follow-up
It is important to note that loss to follow-up is a
fundamental feature of pragmatic trials because loss
to follow-up is a normal process of clinical care in
the real world. We prevented it from causing bias in
CHAP by not adding artificial follow-up clinic visits
for patients who did not attend. Instead, we used
independent administrative databases that recorded
the outcomes for all community dwelling residents,
regardless of whether they participated in the pro-
gram or not or whether they moved in, out or
between communities during the study period
(Table 1). We then applied the intention-to-treat
(TT) principle to analyze the data, by including all
residents aged 65 years or older in the control and
intervention communities. In fact, ITT analysis is the
most appropriate way to answer the question of
whether an intervention works under usual condi-
tions [6, 22].
Fig. 1 PRECIS score for the CHAP trial at the end of trial. The green dots represent the investigators’ scores along the pragmatic-explanatory
continuum (4 = explanatory; 0 = pragmatic). All investigators scored the CHAP trial as pragmatic
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Criticism 2: Non-adherence to study intervention
Non-adherence, a normal process in clinical care in
the real world, is fundamental to pragmatic trials be-
cause they are designed to study real-world practice.
Thus, “…changes in individual patients’ treatment
reflect normal clinical practice…” [9]. We prevented it
from causing bias in CHAP by using ITT analysis to
describe the real-world situation. We did not adjust for
whether or not the participant attended any of the
CHAP sessions, followed up on the medical advice
from their physicians, or adhered to their hypertension
or CVD medications.
Criticism 3: Unblinded patients and physicians and patient
self-assessments
Our intent was to preserve the ecology of normal
care, where doctors know what they are prescribing
and patients know what they are receiving (that
is, people act as they would normally without the in-
fluence of knowing they are part of a trial). No one
is blinded. Therefore, unblinding is fundamental to
pragmatic trials to “…preserve the ecology of care…”
[9]. Our strategy to prevent it from causing bias in
CHAP involved independent adjudication of out-
comes; measuring hospitalizations for CVD-related
events that may be major consequences of hyperten-
sion. These were determined through administrative
databases, not self-reports. Housed at the Institute for
Clinical Evaluative Sciences (www.ices.on.ca), these
databases include routinely collected administrative
health data (see Table 2). The datasets have been
assessed for reliability, completeness and validity, and
have been widely used in health services research
[23–26].
Criticism 4: Less perfect experiments than efficacy trials
Pragmatic trials, like the CHAP trial are evidently not
designed to answer questions about efficacy, but are
the ideal strategy for answering questions about effect-
iveness. Efficacy and pragmatic trials should not be
compared in this way as they seek to answer entirely dif-
ferent questions. In the CHAP trial, the efficacy of blood
pressure measurements, CVD risk assessment, education
and referral were never in question but rather the effect-
iveness of organizing these services in a community
setting.
Criticism 5: Compromising internal validity to achieve
generalizability
For pragmatic trials, “internal validity” would be
compromised if the real-world conditions were al-
tered - that is, if no crossovers were allowed, pa-
tients or clinicians were blinded, or artificial follow-
up visits were created to minimize loss-to-follow up.
In fact, the trial would then no longer be pragmatic.
A problem with this criticism is that the critics in-
appropriately judge the internal validity of a prag-
matic trial by applying criteria that are appropriate
for explanatory trials; this is a major source of confu-
sion about pragmatic trials. We ensured the internal
validity of the CHAP trial by preserving the natural
process of care in the real world and by using other
techniques - such as random allocation of the inter-
vention - to minimize the potential for a bias in its
conclusions.
Criticism 6: Large sample size requirements for small
treatment effects
Finding small treatment effects in heterogeneous pop-
ulations is vital to improving health care [27]. At a
population level, small differences can lead to sub-
stantial improvements in health and decreases in
resource utilization and costs. The key challenge
raised by this criticism is that of feasibility [28]. We
made CHAP feasible by the following: including
everyone aged 65 years or over who lived in the target
communities; using existing community resources
such as lead community organizations to coordinate
the CHAP program; recruiting community-based fam-
ily physicians to send out letters to all their eligible
patients, inviting them to attend BP clinics set-up at
the local pharmacies, which were manned by commu-
nity peer health volunteers and mentors to assess
CVD risk and measure BP; relying on community
health nurses to ensure quality control; and using
existing administrative databases for outcome assess-
ment. The economic analysis of the CHAP trial
showed that the real cost was on average CAN $20
per eligible resident aged at least 65 years old, and
cost neutral (that is, there were no statistically signifi-
cant differences in resource utilization or cost for
hospitalizations, emergency department and physician
visits, or prescription drugs between the CHAP arm
and usual care) [29]. In fact, comparing the per-
patient cost of the CHAP trial to that of most
CVD explanatory trials (at least CAN $5500 per pa-
tient) revealed that that CHAP was extremely inex-
pensive [30].
Conclusions
In addition to the arguments made above, other re-
searchers have demonstrated that outcomes in patients
who receive care in the context of an explanatory RCT
(ideal circumstances) are neither better nor worse than
in patients who receive care in real world (or pragmatic)
circumstances [31, 32].
In May 2012, Dr. Sackett organized a special
session on “Confusions and controversies around
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pragmatic trials” at the Society of Clinical Trials an-
nual meeting in Miami, USA. In his usual thought-
provoking manner, he challenged the audience to
think seriously about the basis for these common
criticisms of pragmatic trials: “Are pragmatic trialists
dancing with the devil or is it simply the confusion
about the question being asked?” He gave the follow-
ing analogy1:
Table 2 Some key resources on pragmatic trials
Topic Resource
The what, how, and why 1 Sackett DL. Clinician-trialist rounds: 16. Mind your explanatory and pragmatic attitudes! - part 1:
what? Clin Trials. 2013; 10(3):495–8.
2 Macpherson H. Pragmatic clinical trials. Complement Ther Med. 2004 Jun-Sep; 12(2–3):136–40.
3 Sackett DL. Clinician-trialist rounds: 17. Mind your explanatory and pragmatic attitudes! Part 2:
How? Clin Trials. 2013 Aug; 10(4):633–6.
4 Staa TP, Goldacre B, Gulliford M, Cassell J, Pirmohamed M, Taweel A, et al. Pragmatic randomised
trials using routine electronic health records: putting them to the test. BMJ. 2012; 344:e55.
5 McMahon AD. Study control, violators, inclusion criteria and defining explanatory and pragmatic
trials. Stat Med. 2002 May 30; 21(10):1365–76.
6 Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for
decision making in clinical and health policy. JAMA. 2003 Sep 24; 290(12):1624–32.
7 Yoong SL, Wolfenden L, Clinton-McHarg T, Waters E, Pettman TL, Steele E, Wiggers J: Exploring
the pragmatic and explanatory study design on outcomes of systematic reviews of public health
interventions: a case study on obesity prevention trials. J Public Health (Oxf) 2014, 36(1):170–176.
Ethical issues pragmatic trials using
cluster randomization
8 Hutton JL. Are distinctive ethical principles required for cluster randomized controlled trials? Stat
Med. 2001 Feb 15; 20(3):473–88.
9 McRae AD, Weijer C, Binik A, Grimshaw JM, Boruch R, Brehaut JC, et al. When is informed consent
required in cluster randomized trials in health research? Trials. 2011; 12:202.
10 Chaudhry SH, Brehaut JC, Grimshaw JM, Weijer C, Boruch R, Donner A, et al. Challenges in the
research ethics review of cluster randomized trials: international survey of investigators. Clin Trials.
2013 Apr; 10(2):257–68.
PRECIS (pragmatic-explanatory continuum
indicator summary) design tool and applications
11 Riddle DL, Johnson RE, Jensen MP, Keefe FJ, Kroenke K, Bair MJ, et al. The Pragmatic-
Explanatory Continuum Indicator Summary (PRECIS) instrument was useful for refining a
randomized trial design: experiences from an investigative team. J Clin Epidemiol. 2010 Nov;
63(11):1271–5.
12 Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, et al. A pragmatic-
explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol.
2009 May; 62(5):464–75.
13 Zwarenstein M, Treweek S. What kind of randomized trials do we need? J Clin Epidemiol. 2009 May;
62(5):461–3.
14 Maclure M. Explaining pragmatic trials to pragmatic policymakers. J Clin Epidemiol. 2009 May;
62(5):476–8.
15 Tosh G, Soares-Weiser K, Adams CE. Pragmatic vs explanatory trials: the pragmascope tool to
help measure differences in protocols of mental health
16 Randomized controlled trials. Dialogues in clinical neuroscience. 2011; 13(2):209–15.
17 Koppenaal T, Linmans J, Knottnerus JA, Spigt M. Pragmatic vs. explanatory: an adaptation of the
PRECIS tool helps to judge the applicability of systematic reviews for daily practice. J Clin
Epidemiol. 2011 Oct; 64(10):1095–101.
18 Selby P, Brosky G, Oh PI, Raymond V, Ranger S. How pragmatic or explanatory is the
randomized, controlled trial? The application and enhancement of the PRECIS tool to the
evaluation of a smoking cessation trial. BMC Med Res Methodol. 2012; 12:101.
Reporting of pragmatic trials 19 Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, et al. Improving the
reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008; 337:a2390.
20 Campbell MK, Piaggio G, Elbourne DR, Altman DG. Consort 2010 statement: extension to cluster
randomised trials. BMJ. 2012; 345:e5661.
21 Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, et al. CONSORT for reporting
randomised trials in journal and conference abstracts. Lancet. 2008 Jan 26; 371(9609):281–3.
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Results from explanatory and pragmatic trials contribute
to the body of knowledge needed to inform healthcare
practice and policy. Knowledge translation efforts that em-
ploy pragmatic trial methods are imperative, especially for
optimal management of chronic health conditions. Prag-
matic trials aim to assess the effectiveness of therapies or
interventions under routine care (real-world) conditions.
The key is to guard against biased conclusions. However, it
is also important to think about “bias” and “validity” in the
context of “effect under routine care.” Tampering with rou-
tine care conditions may actually lead to biased results on
whether therapies work in the real-world settings.
Endnote
1Dave Sackett attributed this to Tjeerd-Pieter van Staa,
head of research and honorary professor of epidemiology
at the London School of Hygiene and Tropical Medicine,
London UK.
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